September 2014 RXMD 3(a)(10) transaction initiated
Dec 29, 2014
In August, we reached our first major accomplishment of the year. After months of negotiation and hard work, the company finalized our debt exchange transaction with Tarpon Bay Partners, LLC.
Through the execution of the deal with Tarpon Bay and approval by the Circuit Court for the 3(a)(10) transaction to proceed, the company will be able to eliminate approximately $1.8 million in debt off of its balance sheet in the coming year.
This transaction allowed the company to settle its litigations with creditors and note holders and has significantly improved our cash flow.
The success of the 3(a)(10) is greatly dependent on our ability to prepare and report on our financial condition in an accurate and timely manner.
In September, we took a great leap forward in this regard by filing our unaudited year-end financial statements for 2012 and 2013 through OTC Markets.
These financial statements were then quickly followed up by the filing of our unaudited financial statements for all three quarters of 2014 on November 22nd.
The filings not only presented the company's current financial position to the public, but also presented the great strides the company has made towards achieving profitability by reducing operating costs and liabilities and increasing sales.
Moving forward, we will pursue new avenues of advancement of the PharmCo brand through mergers and acquisitions.
We believe that key partnerships with similarly positioned independent pharmacies will yield economies of scale and unlock unrealized growth potential.
We will also continue to seek other options for raising capital to reduce the dilutive pressure associated with the 3(a)(10) transaction.